Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy

  • Xiao, Yang (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Liu, Jun (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Liu, Yang-Chen (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Guo, Jian-Xong (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Wei, Wei (Department of Medical Oncology, The People's Hospital of Taixing City)
  • Published : 2014.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Methods: Patients who received highly emetogenic chemotherapy were randomly assigned to a treatment group (60 patients) treated with EANI combined with hydrochloride palonosetron, and control group (also 60 patients) given only hydrochloride palonosetron. Chemotherapy related nausea and vomiting were observed and recorded in both groups of patients from the start till the end of chemotherapy. Results: Complete control rates of vomiting in treatment and control group were 40%, and 35%, respectively, without any statistical ly significant difference (p>0.05); however the response rates are 95.0%, 78.3%, respectively, with statistical difference (p<0.05). Complete control rates of nausea in treatment and control group were 36.7%, 30%, respectively, without statistical difference (p>0.05); but the response rates are 90.0%, 76.7%, respectively, with statistical difference (p<0.05). Conclusion: EANI combined with hydrochloride palonosetron for prevention of nausea and vomiting induced by chemotherapy could be more effective than hydrochloride palonosetron alone, and can be recommended for use in prevention and treatment of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.

Keywords

References

  1. Abe H, Mori T, Kawai Y, et al (2013). Feasibility study of docetaxel and cyclophosphamide six- cycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients. Asian Pac J Cancer Prev, 14, 4835-8. https://doi.org/10.7314/APJCP.2013.14.8.4835
  2. Akkuzu G, Talas MS, Ortac F (2014). Functional status in Turkish women with gynecological cancer. Asian Pac J Cancer Prev, 15, 2045-9. https://doi.org/10.7314/APJCP.2014.15.5.2045
  3. Akyuz RG, Ugur O, Elcigil A (2013). Sleep quality in lung cancer patients. Asian Pac J Cancer Prev, 14, 2909-13. https://doi.org/10.7314/APJCP.2013.14.5.2909
  4. Baykara M, Buyukberber S, Ozturk B, et al (2013). Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers. Asian Pac J Cancer Prev, 14, 2557-61. https://doi.org/10.7314/APJCP.2013.14.4.2557
  5. Dranitsaris G, Leung P, Ciotti R, et al (2001). A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. Pharmacoeconomics, 19, 955-67. https://doi.org/10.2165/00019053-200119090-00007
  6. Fu JH, Gao Z, Ren CC, et al (2013). Comparison of clinical efficacy of three different neoadjuvant approaches (chemotherapy combined vaginal intracavitary irradiation, neoadjuvant chemotherapy alone or radiotherapy) combined with surgery for patients with stage Ib2 and IIa2 cervical cancer. Asian Pac J Cancer Prev, 14, 2377-81. https://doi.org/10.7314/APJCP.2013.14.4.2377
  7. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  8. Ingersoll GL, Wasilewski A, Haller M, et a1 (2010). Effect of concord grape juice on chemotherapy-induced nausea and vomiting results of a pilot study. Oncol Nurs Forum, 37, 213-21. https://doi.org/10.1188/10.ONF.213-221
  9. Jordan K, Kasper C, Schmoll HJ (2005). Chemotherapy-induced nausea and vomiting: Current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer, 41, 199. https://doi.org/10.1016/j.ejca.2004.09.026
  10. Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6. https://doi.org/10.7314/APJCP.2013.14.12.7701
  11. Keat CH, Phua G, Abdul Kassim MS, et al (2013). Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? Asian Pac J Cancer Prev, 14, 469-73 https://doi.org/10.7314/APJCP.2013.14.1.469
  12. Kubota H, Taguchi K, Kobayashi D, et al (2013). Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer. Asian Pac J Cancer Prev, 14, 7107-10. https://doi.org/10.7314/APJCP.2013.14.12.7107
  13. Li CH, Liu MY, Liu W, et al (2014). Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 731-6. https://doi.org/10.7314/APJCP.2014.15.2.731
  14. Rabasseda X.Ramosetron (2002). 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc), 38, 75-89. https://doi.org/10.1358/dot.2002.38.2.820104
  15. Tas D, Uncu D, Sendur MA, et al (2014). Acupuncture as a complementary treatment for cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 15, 3139-44. https://doi.org/10.7314/APJCP.2014.15.7.3139
  16. Uygun K, Bilici A, Kaya S, et al (2013). XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Asian Pac J Cancer Prev, 14, 2283-8. https://doi.org/10.7314/APJCP.2013.14.4.2283
  17. Wang JY, Cai Y (2013). Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 6267-71. https://doi.org/10.7314/APJCP.2013.14.11.6267
  18. Wang M, Gu J, Wang HX, et al (2013). Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. Asian Pac J Cancer Prev, 13, 4153-6. https://doi.org/10.7314/APJCP.2012.13.8.4153
  19. Wang SY, Zhu WH, Vargulick S, et al (2013). Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Asian Pac J Cancer Prev, 14, 5995-6000. https://doi.org/10.7314/APJCP.2013.14.10.5995
  20. Wei G, Nie MM, Shen XJ, et al (2014). Experimental study on sustained-release 5-Fluorouracil implantation in canine peritoneum and para-aortic abdominalis. Asian Pac J Cancer Prev, 15, 407-11. https://doi.org/10.7314/APJCP.2014.15.1.407
  21. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
  22. Xu X, Wang L, Xu HQ, et al (2013). Clinical comparison between paclitaxel liposome ($Lipusu^{(R)}$) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4. https://doi.org/10.7314/APJCP.2013.14.4.2591
  23. Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4. https://doi.org/10.7314/APJCP.2013.14.8.4801
  24. Yusuf A, Ahmad Z, Keng SL et al (2013). Quality of life in Malay and Chinese women newly diagnosed with breast cancer in Kelantan, Malaysia. Asian Pac J Cancer Prev, 14, 435-40. https://doi.org/10.7314/APJCP.2013.14.1.435

Cited by

  1. A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5941
  2. Effects of Analgecine on Oxaliplatin-Induced Neurotoxicity in Patients with Gastrointestinal Cancer vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4465
  3. Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.647
  4. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  5. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485